单周期化疗选择的分次剂量多西他赛、顺铂和5-氟尿嘧啶(TPF)诱导化疗后两周期分次TPF序贯根治性手术联合术后放疗治疗局部晚期口腔和口咽鳞状细胞癌的两臂多中心II期试验(TISOC-1)
该II期研究评估分次剂量TPF诱导化疗后手术治疗局部晚期可切除(III/IVA期)口腔和口咽癌的疗效。54例患者中,应答者(第一周期后肿瘤体积缩小≥30%)接受三周期3周方案,非应答者仅一周期后手术及术后放(化)疗。应答者24个月无进展生存率和总生存率均显著优于非应答者,三联治疗方案耐受良好。
要点
- 应答者24个月无进展生存率88.5% vs 非应答者60.6%(P=0.005)。
- 应答者24个月总生存率97.3% vs 非应答者73.7%(P=0.032)。
- 诱导化疗期间最常见3级以上不良事件为中性粒细胞减少(26%)。
核心结论
- 口腔和口咽癌患者对术前分次剂量TPF及术后放(化)疗应答者显示出良好的肿瘤学结果。
- 三联治疗方案耐受良好。
- 以肿瘤应答作为术前诱导化疗持续时间标准的方案值得在III期研究中进一步探讨。
研究设计与样本
- 两臂多中心II期试验,纳入局部晚期可切除(III/IVA期)口腔和口咽鳞状细胞癌患者。
- 54例患者符合方案分析(91%为IVA期,87%男性,72%口咽癌,70%为应答者)。
- TPF分次给药:每周期第1天和第8天给药(多西他赛30 mg/m2、顺铂40 mg/m2、氟尿嘧啶2000 mg/m2每周)。
- 应答者(第一周期后肿瘤体积缩小≥30%)接受三周期3周方案,非应答者仅接受一周期后手术及术后放(化)疗。
- 主要终点为24个月无进展生存率。
主要发现
- 应答者24个月无进展生存率为88.5%,非应答者为60.6%(P=0.005)。
- 应答者24个月总生存率为97.3%,非应答者为73.7%(P=0.032)。
- 原发肿瘤组织病理学完全缓解率在应答者中更高(P=0.015)。
- 术后放(化)疗高风险分类在应答者中更低(P<0.0001)。
- 诱导化疗期间最常见3级以上不良事件为中性粒细胞减少(26%),术后放(化)疗期间为黏膜炎(13%)。
关键数值与推荐
- 应答标准:第一周期后肿瘤体积缩小≥30%。
- 应答者接受三周期3周方案,非应答者仅接受一周期。
- 主要终点24个月无进展生存率:应答者88.5% vs 非应答者60.6%(P=0.005)。
- 24个月总生存率:应答者97.3% vs 非应答者73.7%(P=0.032)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Induction chemotherapy (ICT) with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy is an effective treatment option for locally advanced head and neck cancer. This phase II study investigated the effectivity of a split-dose TPF ICT before surgery for locally advanced resectable (stage III/IVA) oral and oropharyngeal cancer. PATIENTS AND METHODS: Patients received TPF split on two dosages on days 1 and 8 per cycle (30 mg/m2 docetaxel, 40 mg/m2 cisplatin, 2000 mg/m2 fluorouracil per week). Responders (reduction tumor volume ≥30% after first cycle) received three 3-week cycles and non-responders only one cycle before surgery and postoperative radio(chemo)therapy (RCT). The primary endpoint was progression-free survival rate after 24 months. Secondary endpoints were amongst others overall survival, histopathological response to ICT, toxicity, quality of life and swallowing function. RESULTS: Fifty-four patients (91% stage IVA, 87% male, 72% oropharyngeal cancer, 70% responders) were eligible for a per-protocol analysis. The progression-free survival rate after 24 months was 88.5% for responders and 60.6% for non-responders (P = 0.005). The overall survival rate after 24 months was 97.3% for responders and 73.7% for non-responders (P = 0.032). The rate of histopathological complete remission of the primary tumor was higher in responders (P = 0.015). High-risk classification for postoperative RCT was lower in responders (P < 0.0001). The most common grade 3+ adverse event was neutropenia in 26% of patients during ICT and mucositis in 13% during postoperative RCT. During treatment and follow-up quality of life and swallowing function was not different between responders and non-responders. CONCLUSION: Patients with oral and oropharyngeal cancer responding to split-dose TPF before surgery and postoperative RCT show good oncological results. The tri-modal treatment regime was well tolerated. ICT using tumor response as criterion for duration of ICT before surgery of oral and oropharyngeal cancer merits additional investigation in a phase III study. CLINICAL TRIAL NUMBER: NCT01108042.
引用
- Inhestern J, Schmalenberg H, Dietz A, et al. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol. 2017. PMID: 28498880. doi:10.1093/annonc/mdx202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。